Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $55

Benzinga Newsdesk www.benzinga.com Positive 80.7%

Neg 0% Neu 0% Pos 80.7%

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $53 to $55.